Please login to the form below

Not currently logged in

Sigma-Aldrich to restructure its business

Says move will enable it to better address global customers' needs

Sigma-Aldrich is to reorganise its business into three 'market-focused' units, which the company says will enable it to better address the needs of its global customers and drive global sales growth.

The life science and high technology materials company recently reported a drop in profits of 1 per cent to $344m for the first nine months of the year on the back of sales that were up by 4 per cent to $2bn.

From January 1, 2013, the company's three business units will be: applied markets – covering its current diagnostics, testing and industrial markets; a new research markets unit; and SAFC commercial markets - its renamed manufacturing and services business.

The changes will see a number of personnel changes.

Current president of Sigma's research business Frank Wicks will become president applied markets.

Eric Green will move from vice president and managing director of the international region (APLA) to become president of the research markets business unit, which will focus on broadening Sigma's research products offering. Green will also continue to have responsibility for the Latin America region.

Gilles Cottier will continue to lead the SAFC business, which will still serve customers in the life science and electronic markets.

Other management changes at the company will see Gerrit van den Dool shift from managing director of the North American region to managing director of the European region (EMEA). 

Sigma's Jason Apter will also move from his role of chief of staff to become managing director of the Asia Pacific region and will relocate to Singapore.

23rd November 2012

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...